Avance Clinical Signs MOU with Mid-Ship Biomedical to Strengthen Global Clinical Research Collaboration

Adelaide, Australia | North Carolina, USA

On June 28, 2024, Avance Clinical Pty Ltd (Avance) and Mid-Ship Biomedical (Nanjing) Co., Ltd (Mid-Ship) took a significant step towards expanding their global reach by signing a Memorandum of Understanding (MoU). This strategic partnership establishes a framework for collaboration that will enhance the clinical research and development services offered by both organizations.

The collaboration is set to bring awareness of Avance Clinical’s clinical research services in Mainland China, attracting Chinese biotech companies to Australia for Early Phase studies. In parallel, Mid-Ship will gain access to Avance Clinical’s robust network, enabling them to extend their preclinical CRO services to a broader international audience.

Liahna Toy, Vice President of Commercial Business Development at Avance Clinical, emphasized the importance of this partnership: “This MOU marks a pivotal moment in our efforts to bridge the gap between the Chinese and Australian biotech markets. By combining our expertise, we can offer our clients an unparalleled, seamless experience in clinical development that meets the highest standards of quality and regulatory compliance.”

Andy Hu, Business Development Manager at Avance Clinical, added: “This collaboration allows us to tap into the growing demand for early phase studies from Chinese biotechs. Partnering with Mid-Ship strengthens our position in the global market, and we are excited to work together to drive innovation and success for our clients.”

The MOU sets the stage for a long-term partnership that leverages the strengths of both companies. Avance Clinical and Mid-Ship will work closely to promote their combined capabilities, ensuring that clients receive integrated solutions tailored to their unique clinical development needs. Both organizations are committed to maintaining the highest standards of quality and compliance with relevant regulations and guidelines in all activities.

Mid-Ship Biomedical (Nanjing) Co., Ltd is a leading preclinical CRO in China, known for its comprehensive range of services in the biomedical sector. This partnership will further extend their reach into the global market, particularly in the Asia-Pacific region.

For more information about Mid-Ship Biomedical, please visit Mid-Ship Biomedical.

Stay tuned for further updates as Avance Clinical continues to expand its global partnerships and capabilities.

Find out more:

• Learn about the GlobalReady model
• For more information about the benefits of running your next study with Avance Clinical contact us
• Request a Proposal here

Media Contact:

Avance Clinical
media@avancecro.com
Kate Thompson

About Avance Clinical

Avance Clinical is the largest premium full-service Australian and North American CRO delivering quality clinical trials, with globally accepted data, in Australia, New Zealand and the US for international biotechs. The company’s clients are biotechs completing Phase I to Phase III of their drug development program that requires fast, agile, and adaptive solution-oriented clinical research services.

Frost & Sullivan Awards

Avance Clinical, a Frost & Sullivan Asia-Pacific CRO Market Leadership Award recipient for the past four years, has been providing CRO services in the region for more than 26 years.

Pre-clinical through to mid to Late phase

Avance Clinical offers pre-clinical consulting and regulatory services with their experienced ClinicReady team right from pre-clinical through to Phase III clinical services leveraging significant Australian Government incentive rebates of up to 43.5% and rapid start-up regulatory processes.

With experience across more than 120 indications, the CRO can deliver world-class results and high-quality internationally accepted data for FDA and EMA review.

Technology

Avance Clinical uses state-of-the-art technology and gold standard systems across all functional areas to provide clients with the most effective processes. Medidata, Oracle, TrialHub, Certinia, Salesforce, Zelta and Medrio are just some of the technology partners.